Is BBOT or BCYC more undervalued in 2026?

CirclFi compares BridgeBio Oncology Therapeutics (BBOT) and Bicycle Therapeutics plc (BCYC) using 13 institutional-grade valuation models. BBOT has a Quality of Company score of 6.2/10 while BCYC scores 6.1/10.

Which is a better buy — BBOT or BCYC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BBOT and BCYC valuations compare?

BBOT at $8.84 and BCYC at $4.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BBOT vs BCYC Valuation Comparison 2026 — Intrinsic Value Analysis

BBOT

Biotechnology

BridgeBio Oncology Therapeutics

Quality

6.2

out of 10

Value Trap

—

Price

$8.84

Last close

Models

9/13

Active

BCYC

Biotechnology

Bicycle Therapeutics plc

Quality

6.1

out of 10

Value Trap

SAFE

Price

$4.67

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BBOT Fair Value	BBOT Upside	BCYC Fair Value	BCYC Upside
Bayesian DCF	Intrinsic	$2.70	-69.5%	$5.55	+18.7%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.92	-55.6%	$9.86	+111.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BBOT vs BCYC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BBOT vs BCYC — Which Stock Is More Undervalued?

BBOT scores higher with a 6.2/10 quality rating vs BCYC's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BridgeBio Oncology Therapeutics (BBOT) and Bicycle Therapeutics plc (BCYC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BBOT currently trades at $8.84 with a QOC of 6.2/10, while BCYC trades at $4.67 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).